A JAM-A-tetraspanin-αvβ5 integrin complex regulates contact inhibition of locomotion

JAM-A-四跨膜蛋白-αvβ5整合素复合物调节运动的接触抑制

阅读:1
作者:Daniel Kummer ,Tim Steinbacher ,Sonja Thölmann ,Mariel Flavia Schwietzer ,Christian Hartmann ,Simone Horenkamp ,Sabrina Demuth ,Swetha S D Peddibhotla ,Frauke Brinkmann ,Björn Kemper ,Jürgen Schnekenburger ,Matthias Brandt ,Timo Betz ,Ivan Liashkovich ,Ivan U Kouzel ,Victor Shahin ,Nathalie Corvaia ,Klemens Rottner ,Katsiaryna Tarbashevich ,Erez Raz ,Lilo Greune ,M Alexander Schmidt ,Volker Gerke ,Klaus Ebnet

Abstract

Contact inhibition of locomotion (CIL) is a process that regulates cell motility upon collision with other cells. Improper regulation of CIL has been implicated in cancer cell dissemination. Here, we identify the cell adhesion molecule JAM-A as a central regulator of CIL in tumor cells. JAM-A is part of a multimolecular signaling complex in which tetraspanins CD9 and CD81 link JAM-A to αvβ5 integrin. JAM-A binds Csk and inhibits the activity of αvβ5 integrin-associated Src. Loss of JAM-A results in increased activities of downstream effectors of Src, including Erk1/2, Abi1, and paxillin, as well as increased activity of Rac1 at cell-cell contact sites. As a consequence, JAM-A-depleted cells show increased motility, have a higher cell-matrix turnover, and fail to halt migration when colliding with other cells. We also find that proper regulation of CIL depends on αvβ5 integrin engagement. Our findings identify a molecular mechanism that regulates CIL in tumor cells and have implications on tumor cell dissemination.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。